Dismantling the Silos: How Pharma is Restructuring R&D for Generative AI
Top pharmaceutical companies announced a joint initiative this week to standardize their AI operating models for drug discovery. By shifting from traditional sequential R&D to parallel, AI-driven generative hubs, executives project a 40% reduction in time-to-market for new therapeutics.